TBC Amgen Australia Pty Ltd
Product name
TBC
Sponsor
Accepted date
Feb-2024
Active ingredients
blinatumomab
Proposed indication
Indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in
the consolidation phase.
the consolidation phase.
Application type
C (new indication)
Publication date
Feb-2024